REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

RGNX 11.14.2024

Full Press ReleaseSEC FilingsOur RGNX Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
  • 01.13.2025 - AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
  • 12.16.2024 - Ellie Merle

Recent Filings

  • 01.14.2025 - 4/A Statement of changes in beneficial ownership of securities
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.14.2025 - 8-K Current report

-Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE®trialandMichael Kelly, PhD, Chief Scientific Officer of CureDuchenne

ROCKVILLE, Md.,Nov. 14, 2024/PRNewswire/ --REGENXBIO Inc.(Nasdaq: RGNX) today announced that it will host a webcast to discuss the AFFINITY DUCHENNE®pivotal program and new clinical data, including the first functional data from the ongoing Phase I/II study of RGX-202, the company's next-generation gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D.,Arkansas Children's Hospital, andMichael Kelly, PhD, Chief Scientific Officer of CureDuchenne.

Webcast detailsTitle:AFFINITY DUCHENNE Trial of RGX-202: Pivotal Program and Interim Clinical DataDate/Time:Monday, November 18, 2024, at 8:00 a.m. ESTAccess:The live webcast can be accessedhereand in the Investors section ofREGENXBIO'swebsite atwww.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

These updates will also be presented at theAmerican Society of GeneandCell TherapyandMuscular Dystrophy Association2024 Breakthroughs in Muscular Dystrophy conferenceNovember 19, 2024, inChicago.

ABOUTREGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma®for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visitWWW.REGENXBIO.COM.

Contacts:

Dana CormackCorporate Communicationsdcormack@regenxbio.com

Investors:George E. MacDougallInvestor RelationsIR@regenxbio.com

(PRNewsfoto/REGENXBIO Inc.)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-discussing-pivotal-program-and-first-functional-data-from-the-affinity-duchenne-trial-of-rgx-202-302305167.html

SOURCEREGENXBIO Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com